Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,519.60
(
-0.85%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
106.96
(
2.42%
)
Bitcoin
70,317.01
(
0.60%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 167170

Wednesday, 08/06/2014 5:13:36 PM

Wednesday, August 06, 2014 5:13:36 PM

Post# of 257262
PTLA red flag: Management wants to amend the SAP for the phase-3 APEX study of Betrixaban, despite the fact that the trial is 50% enrolled. Sounds like they don’t think the trial will hit the primary endpoint on the total population and are already trying to make an argument for subset data. (Source: Today's 2Q14 CC.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now